Symptoms mirror Omicron’s, that is, fever, cough, fatigue, sore throat, and muscle aches. Though India’s Covid response ...

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who ...

A widely available antiviral medication offers new possibilities for long Covid patients seeking relief from debilitating ...

A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

Scientists are currently studying how well people are protected against severe disease from XFG. Researchers conducted lab ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent ...

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting ...

The expensive medication does little to prevent hospitalisation or death for people who are vaccinated against the virus, a new Australian analysis of randomised controlled trials has found.

New research finds that Paxlovid, a COVID-19 antiviral, had minimal benefit in vaccinated older adults.